Chinese New Drug response data contains ' water ' query

September 23 Evening, the new drug industry (market, interrogation) (600329. SZ) announced that, due to the early release of the company's website semi-annual financial data, violating the disclosure of information requirements, the company received the China Securities Regulatory Commission Tianjin office of the warning letter on September 22, 2013. Earlier, some investors questioned the company's early release of two data containing "moisture", September 24, the company to respond to the reporter.　　Financial profit Po, the current savings rate increased by 1000% August 19, 2013, the "Securities Market weekly" exclusive release of the "New Drug industry official website performance data far better than the Chinese newspaper was questioned fraud investors," the article pointed out that the company suspected the letter in violation of the facts. The company announced on the evening of September 23 that the company received the warning letter issued by the regulator on September 22, 2013, the Tianjin Securities Regulatory Bureau pointed out, "the new drug industry should have been issued on August 15 in the CSRC designated media 2013.5 Annual Bulletin, however,　　The company has disclosed part of its financial data on the company's website as early as July 18. July 18, the company published on the official web site called "Structural adjustment effect in the first half of the new drug industry, the fastest pace of profit growth," the article, one of the contents, "As of the end of June, the new drug industry to achieve the cumulative sales income of 54.4% of the year, Summary report growth of 24.43%　　To achieve the self-employed profit accounted for the annual task of 65.75%, the summary report growth of 24.7%, 17 major varieties of assessment to complete sales revenue accumulated 1.015 billion yuan, an increase of 11.76%, completed the annual task of 50.3%. Tianjin Securities and Regulatory Bureau pointed out that, in accordance with the "Listed Companies Information disclosure management measures" 59th, the information disclosure of the obligation of the Company's Web site and other media to publish information not prior to the designated media.　　The company acts in violation of this provision. In the first half of 2013, the company attributed the net profit of shareholders of listed companies to 189 million, down 41%. The forecast for the 2013 quarterly does not apply to "a significant change in the cumulative net profit at the end of the year to the end of the next reporting period", the company said. As a result, the company reported a 40% decline in net profit Year-on-year, the market quite surprised.　　Since August 15, the company's share price has fallen by as much as 16%, according to the September 24 closing prices, also close to 12%.　　After the publication of the report, the company has seen the data on the website of investors questioned, the company's official website article data may have "moisture", the company suspected fraud investors. The question is focused on two: first, the Chinese newspaper showed that "excluding the profits contributed by the central medicine industry and Saino pharmaceutical in the same period last year, the company's proprietary profit grew 10.08% per cent year-on-year".　　Compared to the aforementioned article mentioned in the "24.7%", a sharp decline. Second, the company also said in the newspaper, "the company 25 large varieties of cumulative sales revenue of 1.059 billion yuan, an increase of 11.63%". and the above website articleChapter shows that "the company 17 major varieties to complete the sales revenue accumulated 1.015 billion yuan, an increase of 11.76%", sales and year-on-year growth is similar, but 17 varieties into 25 varieties. September 24, the "Securities Market weekly" reporter called the company Dong Secret Office, for the 1th, the other side responded, said, "the company's Web site reported in the first half of the 2013 annual profit summary Report growth of 24.7%, the data is based on the summary report caliber, its year-on-year is also the first half of 2012 summary Report The summary is the statistical scope of the operations of the subsidiaries of the data simply superimposed, and the report is the internal merger offset data, so the growth rate down. The reason why the use of summary caliber on the website is that the company is a subordinate enterprise of Sasac, and the reporting data requested by SASAC is the summary report caliber.　　Of course, according to the relevant regulations, this caliber of data can not be published in advance, so the company received a regulatory letter, which the company will pay attention to.　　For the 2nd, the officers responded that "the company also has industrial and commercial operations, the data is the final external sales of information, the Web site published data has not been internally merged offset." September 24, the new drug industry received 0.08%, reported 12.65 Yuan.